Harmony, IDEAYA, and Hoffmann-La Roche partnered to study combination therapy for pancreatic cancer using machine learning.
1 report, 1 independent
Updated Jun 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Harmony, IDEAYA, and Hoffmann-La Roche partnered to study combination therapy for pancreatic cancer using machine learning.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Also in this story
- GSK is submitting data to the FDA regarding potential expansion of its drug indications.
- GSK has launched a competing ROS1 therapy, while Nuvation Bio Inc. presented relevant data at a major medical conference.
The entities involved
-
Harmony
Nothing else this week.
-
Hoffmann-La Roche
Swiss healthcare company
- FDA